Exhibitor login
Techcrunch 17 November 2026

Isomorphic Labs raises $5 billion for drug discovery

Isomorphic Labs raises $5 billion for drug discovery

Isomorphic Labs, an AI platform focused on drug discovery and a spin-off of Google's DeepMind, has recently raised $5 billion in a Series C funding round. This confirms the growing interest and potential of artificial intelligence in the pharmaceutical industry.

The company, founded in 2021, has focused on accelerating the process of developing new drug candidates. By employing advanced algorithms and machine learning, Isomorphic Labs aims to contribute to more efficient and targeted therapies.

This significant investment enables Isomorphic Labs to boost further research and development and to play an active role in current and future clinical trials. This not only strengthens the company's financial position but also its capacity to achieve significant breakthroughs in medicine.

With this funding round, Isomorphic Labs emphasizes the enormous possibilities that AI offers in the biomedical sector. Given the rising costs and the lengthy processes traditionally associated with drug development, leveraging technology provides a viable pathway to achieve greater efficiency.

Read the full article from Techcrunch.